MedTrace Logo

Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™

NCT01999660 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2021-07-27

No results posted yet for this study

Summary

A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation therapy in prostate cancer patients

Conditions

  • Prostate Cancer Patients Treated by Radiotherapy

Interventions

DEVICE

SpaceOAR™ implantation

Sponsors & Collaborators

  • Aix Scientifics

    collaborator INDUSTRY

  • CS Diagnostics GmbH

    lead INDUSTRY

Principal Investigators

  • Razvan Galalae, PD Dr. med. · Clinic for Radiooncology and Radiotherapy, Evangelical Clinics Gelsenkirchen, Germany

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01999660 on ClinicalTrials.gov